In summary, our findings show that both Ad‐CIITA and Ad‐CIITA mutant enhance the immunogenicity of GB for allogenic T‐cells, facilitating efficient tumor cell killing in the presence of either CD4+ or CD8+ T‐cells. The gene discussed is CD4; the disease is neoplasm.